4.3 Article

3,3′,4′,5′-Tetramethoxychalcone Inhibits Human Oral Cancer Cell Proliferation and Migration via p53-mediated Mitochondrial-dependent Apoptosis

期刊

ANTICANCER RESEARCH
卷 34, 期 4, 页码 1811-1819

出版社

INT INST ANTICANCER RESEARCH

关键词

Oral cancer; 3,3 ',4 ',5 '-tetramethoxychalcone; cell proliferation; apoptosis; cell migration; CCL5/CCR5 axis; DNA double-strand breaks

类别

资金

  1. National Science Council, Taiwan [NSC 100-2113-M-324-001-MY3, NSC101-2313-B-039-004-MY3, NSC 101-2811-M-324-001]
  2. China Medical University, Taiwan [CMU102-S-28]
  3. Tomorrow Medicine Foundation

向作者/读者索取更多资源

Background/Aim: The current study aimed to identify an attractive target against human oral squamous cell carcinoma (OSCC). Materials and Methods: The effect of 3,3',4',5' -tetramethoxychalcone (TMC) on OSCC cell proliferation, cell-cycle phase distribution, expression of markers of cell apoptosis, and cell migration were analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, flow cytometry, western blot, and transwell migration assay, respectively. Results: Experimental results revealed that TMC inhibited the OSCC cell proliferation (fifty percent inhibitory concentrations range=1.0-4.5 mu M) by inducing G(2)/M phase arrest of the cell cycle. TMC caused DNA double-strand breaks, and enhanced expression of caspase-3 and -9, poly (ADP-ribose) polymerase, cytochrome c, calpain-1 and -2, phosphorylation of hi stone H2AX, phosphorylation of checkpoint kinases 2, p53, BCL2-antagonist/killer and BCL2-associated x protein, while reducing the mitochondrial membrane potential, and expression of B-cell lymphoma-2. In addition, TMC reduced the migration potential of OSCC cells by attenuating the C-C chemokine ligand 5/C-C chemokine receptor type 5 axis. Conclusion: These data indicate that TMC may be considered an interesting target for further development of chemotherapeutic agents against oral cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据